Redx Pharma pursues reverse merger with Skye to list on Nasdaq
Redx Pharma, a UK fibrosis biotech, is attempting a reverse merger with Skye to gain a Nasdaq listing. This follows a failed attempt in 2023. The company develops ROCK inhibitors.
Related stories
Ramaswamy-backed pain drug firm to go public via reverse merger · Drug development
Immunology drug developer secures $820M in reverse merger push · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Redx tries again at reverse merger, with Skye this time, as route gains steam.” Browse more stories.